Exclusive Human-milk in Preterm NEOnates and Early VASCular Aging Risk Factors (NEOVASC)

Recruiting N/A Interventional Study
Prematurity Vascular Aging
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
1 Day – 5
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
200 (estimated)
Sponsor
Prolacta Bioscience · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

Early vascular aging has its origins in fetal and neonatal life. The NEOVASC clinical trial aims to determine the effects of an exclusive human milk diet in extremely preterm infants on long-term cardiovascular health.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Preterm-born group: Inclusion Criteria: 1. Extremely preterm infants with a birth weight of 500-1250g. 2. Feeding is NPO or exclusive human milk prior to enrollment. 3. Parent(s) willing to sign informed consent.- Exclusion Criteria: 1. Infants with a birth weight \<500g or \>1250g 2. Subjects d…
Contacts

Ursula Kiechl-Kohlendorfer, MD, MSc

+43 512 504 27309

ursula.kohlendorfer@i-med.ac.at

CONTACT

Wolfgang Mitterer, MD

+43 670 2021490

wolfgang.mitterer@student.i-med.ac.at

CONTACT